Loading company…
Previse Dx develops DNA biomarker tests to assess cancer risk and support early detection.
Founded in 2018, Previse Dx develops diagnostic tests and biomarkers, including Esopredict™ for identifying Barrett's oesophagus patients likely to progress to high grade dysplasia or esophageal cancer. Its methods combine standard tests with DNA biomarkers and are designed for patients and providers. Based in Baltimore, US, the company raised USD 3 million in seed funding in March 2023 from the Maryland Technology Development Corporation, including Gaingels, Riptide Venture, and Wexford Science and Technology.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in